Good MorningEquity markets advanced on Tuesday in hopes that stability in the trade outlook would soon emerge. With maximum uncertainty in the air, simply solidifying the outlook regardless of tariffs could be enough to catalyze a significant broad market stock rally. The index is in rebound mode and moving higher, with eyes on the 5,700 level. Moving above it would trigger the market, leading to a retest of the all-time high.
Economic data and earnings are other potential catalysts for stocks this week. The monthly labor data is due, and the first report, the JOLTs report, was weaker than expected but still shows ample job availability. Regarding earnings, reports from Microsoft, Meta Platforms, and Amazon will give a deep look into the state of tech spending, and it is expected to be strong. The question is whether they will outperform consensus estimates and provide positive guidance, and the odds are high they will due to the low bar set by analysts. Featured: Most of 2026's IPO class failed this test (Ad) 
|
Technology | |
It's said about the weather that if you give it a few minutes it will change. The same could be true about sentiment for CrowdStrike Holdings Inc. (NASDAQ: CRWD). The company is a month away from earnings, and the stock is behaving in a volatile fashion. At the beginning of April, CRWD stock was... Read the Full Story |
|
From Our Partners | | CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month.
Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account. | | Watch the free presentation before this Thursday's payout |
|
Consumer Staples | |
Tariff-resistant Altria Group (NYSE: MO) is still a good buy in 2025 because its business profitability is improving despite declining sales. The decline in sales is primarily due to reduced use of smokeable products, offset by increasing use of consumable and smokeless products.
The critical de... Read the Full Story |
|
Industrials | |
A late April 2025 rally in the S&P 500 has sparked a wave of investor optimism, with some asserting that the market has fully absorbed the effects of President Trump’s tariffs. However, this optimism may be premature.
Key indicators point to significant headwinds ahead. Entrenched inf... Read the Full Story |
|
From Our Partners | | Contributing to your 401(k) consistently is good financial behavior - but contributing and optimizing are two different things. High fees, heavy company stock concentration, and target-date funds that follow a formula rather than your situation can quietly erode your balance over time.
74% of U.S. millionaires work with a financial advisor - more than double the general population rate. A fiduciary advisor can review your 401(k) for fees, allocation, and alignment with your actual timeline. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors in their area. | | Take the free quiz to find a fiduciary advisor near you |
|
Consumer Staples | |
Coca-Cola’s (NYSE: KO) stock price can bubble to new highs this year because its Q1 results and guidance update show its everywhere-is-local approach to business and international growth agenda is working.
The company faces headwinds in 2025 like virtually every other S&P 500 business... Read the Full Story |
|
Consumer Staples | |
With tariffs causing markets to waver in 2025, many investors were growing worried about the guidance companies would put out. Analysts expect certain stocks not to give guidance for the rest of the year due to the difficulty in forecasting amid the tariff policy environment.
Additionally, many s... Read the Full Story |
|
From Our Partners | | Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's a checkpoint you skipped.
The Smart Trade Options Checklist puts the 7 most important pre-trade checks on one page. Normally $29.97, it's free today. Run it in about 30 seconds before any options trade to catch the bad ones before they cost you. | | Download the free 7-point options checklist right here |
|
Consumer Discretionary | |
Domino’s Pizza (NASDAQ: DPZ) faces challenges and headwinds in 2025, but its results and guidance show that it can build leverage despite these obstacles. The Q1 results include system-wide growth and improved profitability, attributed to the Hungry for MORE strategy.
Guidance was reaffir... Read the Full Story |
|
Technology | |
Intel (NASDAQ: INTC) reported seemingly positive first-quarter financial results, exceeding expectations for adjusted earnings per share (EPS) and revenue.
However, this initial positive sentiment quickly faded due to the company's very cautious outlook for the second quarter, forecasting break... Read the Full Story |
|
Technology | |
The technology sector, which had been primarily responsible for powering the market’s recent ascent until this year, was at the forefront of the recent downturn, weighed down by global economic uncertainty and a renewed wave of risk-off sentiment. However, within the broader tech landscape, ... Read the Full Story |
|
Communication Services | |
As a disruptor in the computer and technology sector, specifically the telecommunications industry, T-Mobile US (NASDAQ: TMUS) proudly calls itself the "Un-carrier." This originated in March 2013, when they set out to differentiate themselves against the incumbent telecom “carriers” ... Read the Full Story |
|
Industrials | |
From Scotch tape and Ace bandages to Filtrete air filters and Post-It Notes, 3M Co. (NYSE: MMM) products are often taken for granted in everyday life. Yet, when consumers run out of them, that’s when their true value is revealed. The same applies to its stock. The multi-sector conglomerate... Read the Full Story |
|
Wednesday's Early Bird Stock Of The Day Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
